Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) Shares Outstanding (Weighted Average) (2020 - 2025)

Mirum Pharmaceuticals has reported Shares Outstanding (Weighted Average) over the past 6 years, most recently at $50.2 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Weighted Average) at $50.2 million for Q4 2025, up 5.63% from a year ago — trailing twelve months through Dec 2025 was $50.2 million (up 5.63% YoY), and the annual figure for FY2025 was $50.2 million, up 5.63%.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $50.2 million at Mirum Pharmaceuticals, up from $49.8 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for MIRM hit a ceiling of $50.2 million in Q4 2025 and a floor of $30.1 million in Q1 2021.
  • Median Shares Outstanding (Weighted Average) over the past 5 years was $38.4 million (2023), compared with a mean of $39.8 million.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): grew 3.96% in 2022 and later rose 24.56% in 2024.
  • Mirum Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $30.3 million in 2021, then rose by 11.6% to $33.8 million in 2022, then increased by 20.82% to $40.9 million in 2023, then grew by 16.23% to $47.5 million in 2024, then grew by 5.63% to $50.2 million in 2025.
  • The last three reported values for Shares Outstanding (Weighted Average) were $50.2 million (Q4 2025), $49.8 million (Q3 2025), and $49.7 million (Q2 2025) per Business Quant data.